Literature DB >> 9829353

Three- to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease.

N I McDougall1, B T Johnston, J S Collins, R J McFarland, A H Love.   

Abstract

BACKGROUND: Data on the long-term natural history of gastro-oesophageal reflux disease (GORD) are sparse. This prospective study was designed to determine the clinical outcome on the basis of therapeutic requirements 3 to 4.5 years after initial diagnosis of GORD and to identify specific prognostic indicators of a poor outcome.
METHODS: One hundred and one GORD patients were followed up by symptomatic questionnaire 3 to 4.5 years after diagnosis and offered repeat investigation with endoscopy and oesophageal pH monitoring if symptoms persisted.
RESULTS: Seventy-seven (76%) patients responded (mean follow-up period, 39 months; range, 32-54 months); of these, 28 had grade-II or -III oesophagitis at initial endoscopy, 17 had normal endoscopy but abnormal pH monitoring, and 32 had normal investigations but frequent heartburn. At follow-up 32 (42%) were taking acid suppression therapy, and a further 15 patients started acid suppression therapy after repeat investigation indicated a need to do so, giving a total of 47 (61%) patients receiving acid suppression. The following factors predicted a need for acid suppression at follow-up: oesophagitis on initial endoscopy (P = 0.009), abnormal pH monitoring (P = 0.0005), increased age (P < 0.0005), and increased body mass index (BMI) (P = 0.001). Gender, smoking status, alcohol intake, and lower oesophageal sphincter pressure had no prognostic value. Regression analysis confirmed that age (P = 0.0007), BMI (P = 0.04), and endoscopy result (P = 0.04) all independently affected outcome.
CONCLUSIONS: Most GORD patients still require acid suppression therapy 3 to 4.5 years after initial diagnosis. Age, BMI, and presence of oesophagitis at initial endoscopy all independently predict those who will require long-term acid suppression therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829353     DOI: 10.1080/003655298750026688

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  13 in total

Review 1.  Management of gastro-oesophageal reflux disease in general practice.

Authors:  J Dent; R Jones; P Kahrilas; N J Talley
Journal:  BMJ       Date:  2001-02-10

2.  Comparison of presentation and impact on quality of life of gastroesophageal reflux disease between young and old adults in a Chinese population.

Authors:  Shou-Wu Lee; Chia-Ming Chang; Chi-Sen Chang; Ai-Wen Kao; Ming-Chih Chou
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

Review 3.  Heterogeneity of endoscopy negative heartburn: epidemiology and natural history.

Authors:  Fabio Pace; Valentina Casini; Stefano Pallotta
Journal:  World J Gastroenterol       Date:  2008-09-14       Impact factor: 5.742

Review 4.  A review of the epidemiology of Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  Jennifer L Schneider; Douglas A Corley
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-12-03       Impact factor: 3.043

5.  Age and body mass index: significant predictive factors for successful laparoscopic antireflux surgery.

Authors:  Tomoyuki Irino; Hiroya Takeuchi; Soji Ozawa; Yoshiro Saikawa; Takashi Oyama; Kunihiko Hiraiwa; Takahisa Yoshikawa; Masaki Kitajima; Yuko Kitagawa
Journal:  Surg Today       Date:  2010-11-26       Impact factor: 2.549

6.  Outcome of nonerosive gastro-esophageal reflux disease patients with pathological acid exposure.

Authors:  Fabio Pace; Stefano Pallotta; Gianpiero Manes; Annalisa de Leone; Patrizia Zentilin; Luigi Russo; Vincenzo Savarino; Matteo Neri; Enzo Grossi; Rosario Cuomo
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

7.  The role of GABA(A) receptors in the control of transient lower oesophageal sphincter relaxations in the dog.

Authors:  H Beaumont; A-C Jönsson-Rylander; K Carlsson; S Pierrou; M Ahlefelt; L Brändén; J Jensen; G E Boeckxstaens; A Lehmann
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

Review 8.  Body mass index and the efficacy of acid-mediating agents for GERD.

Authors:  Brian C Jacobson
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

Review 9.  Impact of obesity treatment on gastroesophageal reflux disease.

Authors:  Abraham Khan; Aram Kim; Cassandra Sanossian; Fritz Francois
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

10.  CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett's esophagus in a population with high H. pylori infection rate.

Authors:  Angel Ferrández; Rafael Benito; Juan Arenas; María Asunción García-González; Federico Sopeña; Javier Alcedo; Javier Ortego; Ricardo Sainz; Angel Lanas
Journal:  BMC Gastroenterol       Date:  2006-02-16       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.